Literature DB >> 32302722

Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in Wuhan, China.

Xiong Wang1, Wei Liu2, Jinzhu Zhao3, Yanjun Lu1, Xu Wang1, Caizheng Yu2, Shuhua Hu2, Na Shen1, Weiyong Liu1, Ziyong Sun4, Wengang Li5.   

Abstract

More than 1,000 medical workers have been infected with COVID-19 in China. The 80 hospitalized patients included 57 SARS-CoV-2 confirmed and 23 clinically diagnosed. The median age was 39 years, 49 (61.25%) were women, and one patient died. The most common symptoms at onset were fever (65, 81.25%), cough (47, 58.75%), fatigue (28, 35%), myalgia (19, 23.75%), expectoration (19, 23.75%), and diarrhea (15, 18.75%). Patients of frontline medical workers at a single-center hospital showed some unique clinical and laboratory findings compared with other patients in Wuhan and outside of Wuhan. This study provides our experience for other frontline medical workers.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; medical worker; outcome; treatment

Year:  2020        PMID: 32302722      PMCID: PMC7194674          DOI: 10.1016/j.jhin.2020.04.019

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


Introduction

In December 2019, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China, and has spread rapidly [1,2]. Up to April 3rd, 2020, a total of 82,857 confirmed cases have been reported in China. Human-to-human transmission has been confirmed, though initial epidemiological evidence suggested animal-to-human transmission in patients who had visited the Huanan seafood market in Wuhan [3]. SARS-CoV-2 shows close similarity to bat coronaviruses and belongs to the β-coronavirus genus, but is divergent from severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) [4]. The main clinical manifestations of COVID-19 include fever, cough, fatigue, myalgia, and bilateral distribution of ground glass opacity on chest radiograph. Acute respiratory distress syndrome (ARDS) and death occur in severely affected patients. Several studies have reported the clinical characteristics of infected patients in both Wuhan and other cities in China [1,3,[5], [6], [7]]. Frontline medical workers were at high risk of infection; 1716 medical workers were infected up to February 11th, 2020, and 11 of them died up to February 24th, 2020 [8]. However, the clinical investigation of this special population group was insufficient [3]. We aimed to describe the clinical characteristics of 80 hospitalized frontline medical workers with COVID-19 at a single-centre hospital and to compare SARS-CoV-2 confirmed cases with clinically diagnosed cases.

Methods

Data collection

COVID-19 was diagnosed based on positive SARS-CoV-2 nucleic acid test from respiratory tract specimen or based on clinical diagnosis with fever and bilateral involvement on chest radiographs according to the fifth version of the COVID-19 diagnosis and control plan published by the Chinese government. Epidemiological, clinical, laboratory, radiological, treatment, and outcome data on the infected frontline medical workers at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, were obtained from electronic medical records. Information recorded included occupation, exposure history, medical history, symptoms, duration from onset to hospital admission, laboratory test, chest computed tomography (CT), treatment measure, and outcome. Laboratory findings and chest CT were collected on admission to hospital. The Berlin definition of ARDS was adopted [9]. The study was approved by Tongji Hospital Ethics Committee (No. TJ-C2030).

SARS-CoV-2 nucleic acid detection

Throat swab samples were collected, stored in 5 mL virus preservation solution, and virus RNA was extracted within 24 h on the Tianlong PANA9600 automatic nucleic acid extraction system (Tianlong, Xi'an, China) with ready-to-use reagents. The open reading frame 1ab and nucleocapsid protein genes were simultaneously tested with commercial real-time reverse transcription–polymerase chain reaction (RT–PCR) kit from Da An Gene Co. Ltd (Guangzhou, Guangdong, China). RT–PCR assay was performed on the Tianlong Gentier 96E real-time PCR system with the following conditions: incubation at 50°C for 15 min, pre-denaturation at 95°C for 15 min, 45 cycles of denaturation at 94°C for 15 s, and extension at 55°C for 45 s (collecting fluorescence signal). A cycle threshold value (CT) ≥40 for both genes was defined as negative, and CT <40 for both genes was defined as positive. Samples with a single CT <40 required confirmation by retesting.

Analysers used to measure laboratory results

The blood cell count was analysed using the Sysmex XE-2100 haematology analyser (Sysmex, Kobe, Japan). Coagulation tests were conducted by STA-R MAX coagulation analyser (Diagnostica Stago, Saint-Denis, France). Biochemical items were analysed with Cobas C8000 (Roche, Mannheim, Germany). Antibodies against SARS-CoV-2 including IgM and IgG were tested using iFlash3000 (Shenzhen YHLO Biotech Co. Ltd, Shenzhen, China).

Statistical analysis

Patients were classified as SARS-CoV-2 nucleic acid confirmed (NAC) or as clinically diagnosed (CD). The inclusion criteria for CD are listed in Supplementary Table S1. Continuous variables are presented as medians with interquartile (IQR) ranges or as means and standard deviations. Student's t-test was used for normally distributed data; otherwise, Wilcoxon's rank-sum test was used. Categorical variables were analysed using the χ2-test or Fisher's exact test. All analyses were done with SPSS 16 (SPSS, Chicago, IL, USA). P < 0.05 was considered statistically significant.

Results and discussion

The patients were admitted from January 10th to February 24th, 2020. The median age was 39 years (IQR: 32–48.5); 49 (61.25%) were women (Table I ). Nurses accounted for 51.25% of all cases. Hypertension (10; 12.50%) and renal disease (3; 3.75%) were the most common coexisting diseases. The most common symptoms at onset were fever (65; 81.25%), cough (47; 58.75%), fatigue (28; 35%), myalgia (19; 23.75%), expectoration (19; 23.75%), diarrhoea (15; 18.75%), and headache (8; 10%). The median duration from onset to hospital admission was seven days.
Table I

Clinical characteristics, treatment and outcome of 80 frontline medical staff infected with COVID-19 at a single-centre hospital in Wuhan

CharacteristicsAllSARS-CoV-2 confirmedClinically diagnosedP-value
No.805723
Age (years)a39 (32–48.5)40 (33–49)39 (32–48)0.953
Sex (%)
 Male31 (38.75)25 (43.86)6 (26.09)0.139
 Female49 (61.25)32 (56.14)17 (73.91)
Composition (%)
 Doctor23 (28.75)19 (33.33)4 (17.39)0.248
 Nurse41 (51.25)26 (45.61)15 (65.22)
 Other16 (20.00)12 (21.05)4 (17.39)
Comorbidities (%)
 Hypertension10 (12.50)9 (15.79)1 (4.35)0.161
 Diabetes1 (1.25)1 (1.75)00.523
 Cardiovascular disease2 (2.50)1 (1.75)1 (4.35)0.501
 Cerebrovascular disease1 (1.25)1 (1.75)00.523
 Chronic obstructive pulmonary disease1 (1.25)1 (1.75)00.523
 Renal disease3 (3.75)2 (3.51)1 (4.35)0.858
 Liver disease2 (2.50)2 (3.51)00.363
Symptoms (%)
 Fever65 (81.25)48 (84.21)17 (73.91)0.286
 Fatigue28 (35.00)23 (40.35)5 (21.74)0.114
 Myalgia19 (23.75)17 (29.82)2 (8.70)0.044
 Cough47 (58.75)28 (49.12)19 (82.61)0.006
 Expectoration19 (23.75)10 (17.54)9 (39.13)0.040
 Diarrhoea15 (18.75)9 (15.79)6 (26.09)0.286
 Headache8 (10.00)7 (12.28)1 (4.35)0.284
Time from onset to hospital admission (days)a7 (4–8)7 (3–10)6 (4–8)0.936
Admission to intensive care unit4 (5.00)3 (5.26)1 (4.35)0.804
Acute respiratory distress syndrome4 (5.00)2 (3.51)2 (8.70)0.335
Treatment
 Antiviral treatment78 (97.50)56 (98.25)22 (95.65)0.501
 Antibiotics75 (93.75)52 (91.23)23 (100.00)0.142
 Corticosteroid46 (57.50)34 (59.65)12 (52.17)0.540
 Non-invasive ventilation68 (85.00)48 (84.21)20 (86.96)0.756
 Invasive mechanical ventilation2 (2.50)2 (3.51)00.363
 Extracorporeal membrane2 (2.50)2 (3.51)00.363
Outcome
 Discharge78 (97.50)55 (96.49)23 (100.00)0.359
 Death1 (1.25)1 (1.75)00.523
Hospitalization daya20.5 (15–28)21 (17–28)18 (15–30)0.297

Median (interquartile range).

Clinical characteristics, treatment and outcome of 80 frontline medical staff infected with COVID-19 at a single-centre hospital in Wuhan Median (interquartile range). In the NAC group, 17 (29.82%) patients presented myalgia, whereas only two (8.70%) patients had myalgia in the CD group (P = 0.044). Twenty-eight (49.12%) NAC patients had cough, and 19 (82.61%) CD patients had cough (P = 0.006). Expectoration was significantly different between the two groups (17.54% vs 39.13% for NAC and CD groups, respectively; P = 0.040). The clinical characteristics were stratified by sex (Supplementary Table S2). Composition was quite different between males and females. Doctors accounted for 61.29% of males affected, whereas they accounted for 8.16% of females affected. Moreover, 22.58% of males had hypertension, and only 6.12% of females suffered with hypertension. Other aspects of clinical characteristics were similar between males and females. Laboratory tests were performed on hospital admission. Nineteen of the 80 (23.75%) patients showed leucopenia and 38 (47.5%) showed lymphopenia. The platelet and D-dimer levels were within normal range. Twelve (15%) patients showed prolonged prothrombin time (PT), and 13 (26.53%) showed shortened activated partial thromboplastin time (APTT). Nineteen (23.75%) patients showed increased serum creatinine level, and 30 (37.5%) had decreased creatine kinase (CK). Levels of lactate dehydrogenase (LDH), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were increased in 37 (46.25%), 14 (17.5%), and 21 (26.25%) patients, respectively. Bilateral involvement on chest radiographs was observed in all patients except for one (Table II ).
Table II

Laboratory findings on 80 frontline medical staff infected with COVID-19 on hospital admission

VariablesAllSARS-CoV-2 confirmed (N = 57)Clinically diagnosed (N = 23)ReferenceP-value
Wilcoxon rank-sum testχ2-test
White blood cell count (×109/L)a4.38 (3.58–5.53)4.31 (3.49–5.27)4.90 (3.64–5.73)3.50–9.500.2530.231
 Increased5 (6.25%)2 (3.51%)3 (13.04%)
 Decreased19 (23.75%)15 (26.32%)4 (17.39%)
Neutrophil count (×109/L)a2.55 (2.01–3.66)2.43 (1.97–3.55)2.86 (2.18–3.83)1.80–6.300.4010.714
 Increased8 (10.00%)5 (8.77%)3 (13.04%)
 Decreased14 (17.50%)11 (19.30%)3 (13.04%)
Lymphocyte count (×109/L)a1.12 (0.83–1.59)1.09 (0.76–1.49)1.33 (1.04–1.88)1.10–3.200.0190.148
 Increased
 Decreased38 (47.50%)30 (52.63%)8 (34.78%)
Monocyte count (×109/L)a0.41 (0.32–0.53)0.41 (0.32–0.52)0.41 (0.33–0.53)0.10–0.600.8610.704
 Increased12 (15.00%)8 (14.04%)4 (17.39%)
 Decreased
Platelet count (×109/L)a181.5 (148.00–227.50)180.00 (148.00–218.00)212.00 (148.00–260.00)125.0–350.00.3390.827
 Increased3 (3.75%)2 (3.51%)1 (4.35%)
 Decreased8 (10.00%)5 (8.77%)3 (13.04%)
D-dimer (mg/L)a0.40 (0.29–0.58)0.40 (0.29–0.57)0.40 (0.27–0.59)<0.220.864
 Increased
 Decreased
Prothrombin time (s)a14.00 (12.90–14.00)13.30 (12.90–14.00)13.70 (13.00–14.00)11.5–14.50.4690.909
 Increased12 (15.00%)8 (14.04%)4 (17.39%)
 Decreased3 (3.75%)2 (3.51%)1 (4.35%)
Activated partial thromboplastin time (s)a41.80 (37.20–44.10)42.60 (37.70–44.10)40.35 (35.50–43.90)29.0–42.00.1740.880
 Increased
 Decreased13 (26.53%)8 (25.81%)5 (27.78%)
Creatinine (μmol/L)a63.00 (51.00–84.00)73.00 (56.00–84.00)54.00 (47.00–86.00)45–840.0510.907
 Increased19 (23.75%)13 (22.81%)6 (26.09%)
 Decreased6 (7.50%)4 (7.02%)2 (8.70%)
Creatine kinase (U/L)a78.50 (49.00–151.00)77.00 (49.00–155.00)81.50 (42.00–122.00)18–1980.7210.962
 Increased8 (10.00%)6 (10.53%)2 (8.70%)
 Decreased30 (37.5%)21 (36.84%)9 (39.13%)
Lactate dehydrogenase (U/L)a208.00 (185.00–266.00)205.00 (183.00–253.00)216.00 (190.00–296.00)135–2140.3760.587
 Increased37 (46.25%)25 (43.86%)12 (52.17%)
 Decreased2 (2.50%)1 (1.75%)1 (4.35%)
Alanine aminotransferase (U/L)a18.00 (12.00–26.00)18.50 (12.00–26.00)16.00 (12.00–27.00)≤330.8210.505
 Increased14 (17.50%)11 (19.30%)3 (13.04%)
 Decreased
Aspartate aminotransferase (U/L)a22.00 (18.00–32.00)23.50 (19.50–33.00)21.00 (17.00–29.00)≤320.2140.560
 Increased21 (26.25%)16 (28.07%)5 (21.74%)
 Decreased
Bilateral involvement on chest radiographs79 (98.75%)56 (98.25%)23 (100.00%)0.522

Mean (SD).

Laboratory findings on 80 frontline medical staff infected with COVID-19 on hospital admission Mean (SD). NAC and CD groups showed similar laboratory findings except for lymphocyte count, which was lower in the NAC group. Thirty (52.63%) NAC patients showed lymphopenia, compared with only eight (34.78%) CD patients. Laboratory findings showed significant differences between males and females (Supplementary Table S3). Females had higher platelet count than did males. Of males, 19.35% had decreased platelet count, compared with only 4.08% for females. APTT was slightly different between males and females. Males had higher levels of creatinine than did females. Of males, 54.84% had increased creatinine, compared with only 4.08% of females. Moreover, males had higher levels of CK, ALT, and AST than did females. Four of the 80 patients were transferred to intensive care unit (ICU) for acute respiratory distress syndrome (ARDS). Seventy-eight (97.5%) patients received antiviral treatment including umifenovir (Arbidol; Pharmstandard, Dolgoprudny, Russia), lopinavir/ritonavir (Kaletra; Abbott, Abbott Park, IL, USA), and interferon-α; 75 (93.75%) received antibiotic treatment; and 46 (57.5%) received corticosteroid treatment. Sixty-eight (85%) patients received non-invasive ventilation; two (2.5%) received invasive ventilation and further received extracorporeal membrane oxygenation (ECMO). At this point, 78 (97.5%) patients had been discharged, one patient had died, and one was still in ICU (Table I). The median time of hospitalization was 20.5 days. No significant difference was found between NAC and CD groups in treatment and outcome. No significant difference was found between males and females in treatment and outcome. This is the first report on hospitalized frontline medical workers with COVID-19 including 57 SARS-CoV-2 confirmed and 23 clinically diagnosed cases. None of these workers had visited Huanan seafood market in Wuhan. The median age was 39 years (IQR: 32–48.5), similar to that in a report from Zhejiang province, China (41 years; IQR: 32–52), but different from a local study from Wuhan including 138 patients (56 years; IQR: 42–68) [7]. Female patients accounted for the majority (61.25%) of all cases in our study, quite different from other studies [1,3,7]. This suggests that the infected frontline medical workers were younger than other patients, and female workers were infected more than male workers, consistent with the large number of nurses serving in the hospital. Hypertension was the most common comorbidity, consistent with other studies from Wuhan, whereas liver disease was the most common comorbidity in Zhejiang province [3,7]. Wuhan is an inland city and Zhejiang includes several coastal cities; whether the difference in comorbidity is caused by the geographic difference is unknown. The most common symptoms were similar to those in other studies; however, a higher ratio of diarrhoea was observed in the frontline medical workers (18.75%) than in other patients in Wuhan (10.1%) and Zhejiang province (8%) [3,7]. The median time from onset to hospital admission was two days in Zhejiang province, shorter than that in our study (seven days), which may be due to the urgent alarm of the government from January 23rd, 2020. The NAC group had a higher ratio of myalgia but lower ratio of cough and expectoration than the CD group. The clinical features varied between male and female patients. These data indicate that the frontline medical workers showed some unique characteristics. Laboratory findings were consistent with previous studies, including leucopenia, lymphopenia, increased LDH, ALT, and AST. Yet, some results were different from other studies. D-dimer levels were all in normal range, whereas several other studies showed increased D-dimer [6]. In a recent study, Tang et al. found that COVID-19 non-survivors showed significantly higher level of D-dimer than did surviving patients [10]. Some medical workers had already taken actions before hospital admission, and most patients experienced mild-to-moderate symptoms in our study. Twelve (15%) patients showed prolonged PT and three (3.75%) showed decreased PT; these proportions were 5% and 30%, respectively, in a previous study including 99 patients in Wuhan [6]. Slightly prolonged PT was also observed in another study in our centre [10]. Coagulation test may be influenced by several factors of patients. The laboratory findings also varied between male and female patients. Moreover, NAC group had lower level of lymphocyte than CD group. The treatments in this hospital were different than in other regions. Antibiotics were administered for 93.75% of all cases, compared with 45% in Zhejiang province [7]. Moreover, corticosteroid treatment was carried out in 57.5% of all patients, compared with only 26% in Zhejiang and 44.9% in another hospital in Wuhan [6,7]. The mortality rate was 1.25% in our study, compared with 4.3% in other patients in Wuhan [6]. Both NAC and CD groups received similar treatments and showed similar outcomes. Sixteen of the 23 CD patients received an antibody test against SARS-CoV-2 including IgM and IgG. All 16 patients showed positive IgG, and five out of 16 patients had positive IgG and IgM. Therefore, the negative nuclear acid result of SARS-CoV-2 in CD patients might be due to the low sensitivity of the method. In conclusion, patients of frontline medical workers at a single-centre hospital showed some unique clinical and laboratory findings compared with other patients in Wuhan and in other regions.
  9 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  Acute respiratory distress syndrome: the Berlin Definition.

Authors:  V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

3.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

4.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

5.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.

Authors:  Xiao-Wei Xu; Xiao-Xin Wu; Xian-Gao Jiang; Kai-Jin Xu; Ling-Jun Ying; Chun-Lian Ma; Shi-Bo Li; Hua-Ying Wang; Sheng Zhang; Hai-Nv Gao; Ji-Fang Sheng; Hong-Liu Cai; Yun-Qing Qiu; Lan-Juan Li
Journal:  BMJ       Date:  2020-02-19

6.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.

Authors:  Ning Tang; Dengju Li; Xiong Wang; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-03-13       Impact factor: 5.824

7.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

8.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

9.  First Case of 2019 Novel Coronavirus in the United States.

Authors:  Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai
Journal:  N Engl J Med       Date:  2020-01-31       Impact factor: 91.245

  9 in total
  15 in total

Review 1.  Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.

Authors:  Kiarash Saleki; Shakila Yaribash; Mohammad Banazadeh; Ehsan Hajihosseinlou; Mahdi Gouravani; Amene Saghazadeh; Nima Rezaei
Journal:  Eur J Pharmacol       Date:  2021-06-12       Impact factor: 4.432

Review 2.  Clinical and epidemiological profile of COVID-19 in health professionals: a review of the literature.

Authors:  Érika de Fátima Machado Soares; Amanda Júlia de Arruda Magalhães; Ayara Jhulia Palmeira Dantas Lima; Danielle Nascimento Nunes; Louryanne de Castro Silva; Lucas Gomes Santos; Regicley Vieira da Silva; Vitória Ingryd Dos Santos Cardoso; Yasmin Vitória Silva Nobre; Carlos Dornels Freire de Souza
Journal:  Rev Bras Med Trab       Date:  2021-09-30

3.  Musculoskeletal symptoms in SARS-CoV-2 (COVID-19) patients.

Authors:  Lucio Cipollaro; Lorenzo Giordano; Johnny Padulo; Francesco Oliva; Nicola Maffulli
Journal:  J Orthop Surg Res       Date:  2020-05-18       Impact factor: 2.359

Review 4.  No Autopsies on COVID-19 Deaths: A Missed Opportunity and the Lockdown of Science.

Authors:  Monica Salerno; Francesco Sessa; Amalia Piscopo; Angelo Montana; Marco Torrisi; Federico Patanè; Paolo Murabito; Giovanni Li Volti; Cristoforo Pomara
Journal:  J Clin Med       Date:  2020-05-14       Impact factor: 4.241

5.  Low Albumin Levels Are Associated with Poorer Outcomes in a Case Series of COVID-19 Patients in Spain: A Retrospective Cohort Study.

Authors:  Roberto de la Rica; Marcio Borges; Maria Aranda; Alberto Del Castillo; Antonia Socias; Antoni Payeras; Gemma Rialp; Lorenzo Socias; Lluis Masmiquel; Marta Gonzalez-Freire
Journal:  Microorganisms       Date:  2020-07-24

Review 6.  Peripheral Nervous System Manifestations Associated with COVID-19.

Authors:  Sasan Andalib; José Biller; Mario Di Napoli; Narges Moghimi; Louise D McCullough; Clio A Rubinos; Christa O'Hana Nobleza; M Reza Azarpazhooh; Luciana Catanese; Isabel Elicer; Mostafa Jafari; Fabrizio Liberati; Claudia Camejo; Michel Torbey; Afshin A Divani
Journal:  Curr Neurol Neurosci Rep       Date:  2021-02-14       Impact factor: 5.081

7.  Impact of the COVID-19 Pandemic on Healthcare Workers' Risk of Infection and Outcomes in a Large, Integrated Health System.

Authors:  Anita D Misra-Hebert; Lara Jehi; Xinge Ji; Amy S Nowacki; Steven Gordon; Paul Terpeluk; Mina K Chung; Reena Mehra; Katherine M Dell; Nathan Pennell; Aaron Hamilton; Alex Milinovich; Michael W Kattan; James B Young
Journal:  J Gen Intern Med       Date:  2020-09-01       Impact factor: 5.128

8.  Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19.

Authors:  Anand V Kulkarni; Pramod Kumar; Harsh Vardhan Tevethia; Madhumita Premkumar; Juan Pablo Arab; Roberto Candia; Rupjyoti Talukdar; Mithun Sharma; Xiaolong Qi; Padaki Nagaraja Rao; Duvvuru Nageshwar Reddy
Journal:  Aliment Pharmacol Ther       Date:  2020-07-08       Impact factor: 9.524

Review 9.  Neuromuscular presentations in patients with COVID-19.

Authors:  Vimal Kumar Paliwal; Ravindra Kumar Garg; Ankit Gupta; Nidhi Tejan
Journal:  Neurol Sci       Date:  2020-09-15       Impact factor: 3.307

10.  Simultaneous dengue and COVID-19 epidemics: Difficult days ahead?

Authors:  Mathieu Nacher; Maylis Douine; Mélanie Gaillet; Claude Flamand; Dominique Rousset; Cyril Rousseau; Chedli Mahdaoui; Stanley Carroll; Audrey Valdes; Nathalie Passard; Gabriel Carles; Félix Djossou; Magalie Demar; Loïc Epelboin
Journal:  PLoS Negl Trop Dis       Date:  2020-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.